CA2288964A1 - Nouveau procede d'administration de thrombopoietine - Google Patents

Nouveau procede d'administration de thrombopoietine Download PDF

Info

Publication number
CA2288964A1
CA2288964A1 CA002288964A CA2288964A CA2288964A1 CA 2288964 A1 CA2288964 A1 CA 2288964A1 CA 002288964 A CA002288964 A CA 002288964A CA 2288964 A CA2288964 A CA 2288964A CA 2288964 A1 CA2288964 A1 CA 2288964A1
Authority
CA
Canada
Prior art keywords
tpo
dose
administered
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002288964A
Other languages
English (en)
Inventor
Robert L. Cohen
Dan L. Eaton
Andrew J.S. Jones
Dennie V. Jones
Michael F. Powell
Theresa D. Sweeney
G. Roger Thomas
Gerard Wagemaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2288964A1 publication Critical patent/CA2288964A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des matières de thrombopoïétine pouvant être administrées de façon à obtenir un effet sensiblement thérapeutique en une seule prise quotidienne ou en plusieurs prises à faible dose. On obtient une inversion de la thrombocytopénie en administrant à un patient atteint de cette maladie ou nécessitant un tel traitement une seule dose quotidienne ou de multiples faibles doses d'une quantité thérapeutiquement efficace d'une thrombopoïétine.
CA002288964A 1997-05-21 1998-05-21 Nouveau procede d'administration de thrombopoietine Abandoned CA2288964A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85976797A 1997-05-21 1997-05-21
US08/859,767 1997-05-21
US1501698A 1998-01-28 1998-01-28
US09/015,016 1998-01-28
PCT/US1998/010475 WO1998052598A1 (fr) 1997-05-21 1998-05-21 Nouveau procede d'administration de thrombopoietine

Publications (1)

Publication Number Publication Date
CA2288964A1 true CA2288964A1 (fr) 1998-11-26

Family

ID=26686844

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002288964A Abandoned CA2288964A1 (fr) 1997-05-21 1998-05-21 Nouveau procede d'administration de thrombopoietine

Country Status (5)

Country Link
EP (1) EP0983082A1 (fr)
JP (1) JP4562815B2 (fr)
AU (1) AU7589898A (fr)
CA (1) CA2288964A1 (fr)
WO (1) WO1998052598A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253935T1 (de) * 1999-01-28 2003-11-15 Univ Texas Erhöhung von zirkulierenden plättchen mit thrombopoietinzusammensetzungen
DE19956156A1 (de) * 1999-11-23 2001-06-13 Univ Eberhard Karls Verfahren zur Aufbereitung eines Präparates von Thrombozyten und Thrombozytenpräparat
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
EP1365808B1 (fr) * 2000-11-06 2011-01-19 Pharma Mar, S.A. Compositions contenant d'ecteinascidin 743 pour le traitement anti-tumeur
AU2003271194A1 (en) * 2003-10-09 2005-04-21 Daewoong Co., Ltd. Process for purifying human thrombopoietin with high content of sialic acid
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP2310035B1 (fr) * 2008-06-16 2015-08-26 University Of Rochester Analogues de facteur de croissance de fibroblaste (fgf) et leurs utilisations
EP3406260B1 (fr) * 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Inhibiteurs de kinases dépendant de la cycline et leurs procédés d'utilisation
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
DE102011085695A1 (de) * 2011-11-03 2013-05-08 Jörg Pohl Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
CN109310733A (zh) 2016-02-23 2019-02-05 百欧林纳克斯有限公司 治疗急性骨髓性白血病的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
JP2991630B2 (ja) * 1994-02-14 1999-12-20 麒麟麦酒株式会社 ヒトｔｐｏ活性を有するタンパク質をコードするｄｎａ
CN1229385C (zh) * 1994-03-31 2005-11-30 安姆根有限公司 刺激巨核细胞生长和分化的组合物及方法
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only

Also Published As

Publication number Publication date
JP2001526689A (ja) 2001-12-18
EP0983082A1 (fr) 2000-03-08
WO1998052598A1 (fr) 1998-11-26
JP4562815B2 (ja) 2010-10-13
AU7589898A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
ES2314999T3 (es) Factor celular madre.
AU711639B2 (en) Novel administration of thrombopoietin
US6013067A (en) Methods for increasing hematopoietic cells
CA2288964A1 (fr) Nouveau procede d'administration de thrombopoietine
JP2002512006A (ja) ＴＮＦ受容体スーパーファミリーの一員である成熟ＦＬＩＮＴ（ｍＦＬＩＮＴ）ポリペプチド、または、ＯＰＧ３の治療上の適用
NZ509576A (en) FLT3-L mutant polypeptides and nucleic acids and their use in treatment
CA2212006A1 (fr) Nouveaux ligands se fixant a c-mpl
CA2170979A1 (fr) Augmentation du nombre de cellules souches hematopoietiques dans le sang peripherique par transformation du facteur de croissance beta
JP2853905B2 (ja) 未結合ｍｐｌ受容体を用いた血小板産生を刺激するための組成物
Haznedaroglu et al. Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions
JPH05247095A (ja) 新規な巨核球増幅因子とその製造方法および医薬組成物
AU2006201129B2 (en) Novel administration of thrombopoietin
EP3873476A1 (fr) Procédé de polythérapie pour le traitement de néoplasmes myéloprolifératifs avec un conjugué d'interleukine -3 - toxine diphtérique humaine en combinaison avec d'autres agents
US6403553B1 (en) Use of polypeptides for treating thrombocytopenia
EP1033997B1 (fr) Technique visant a mobiliser des cellules souches hematopoietiques
JPH11506747A (ja) 治療におけるリンホトキシン及びトロンボポエチンの使用
JPH05255396A (ja) ヒトインターロイキン１１様蛋白とその製造方法および医薬組成物
MXPA97009244A (en) Methods to increase hematopoyeti cells
JPWO2002015926A1 (ja) ｃ−ｍｐｌリガンドを含有する、血小板及び赤血球を増加させるための医薬組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20141015